Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine.

Nanomedicine is a promising strategy for improving clinical outcomes for cancer therapies, by improving drug efficacy through enhanced delivery to disease sites. It is of importance for ultimate clinical success to consider the contributing factors to achieving this goal, such as size, chemistry and functionality of nanoparticle delivery systems, and how these parameters influence tumor localization and uptake. This short review will first discuss the evolution and progress of polymeric nanoparti-cles for cancer drug delivery and the current challenges that remain to be addressed. Strategies for overcoming the limita-tions of passive targeting through active targeting approaches, and the current state of such nanomedicines in the clinic will be highlighted. Finally, novel approaches towards the design of active targeted nanoparticles building on our growing under-standing of nano-bio interactions are considered, in order to shed light on future design considerations for accelerating clini-cal translation of nanomedicines.

• Publication year

  2019

• Venue

  Bioconjugate chemistry

• Publication date

  2019-08-23

• Fields of study

  Medicine, Materials Science, Chemistry, Engineering

• Identifiers
  DOI 10.1021/acs.bioconjchem.9b00456PMID 31441642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles.

  2019cited by this paper
• Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.

  2019cited by this paper
• Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44.

  2019cited by this paper
• Estimation of clinical trial success rates and related parameters

  2018cited by this paper
• Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies

  2018cited by this paper
• Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications

  2018cited by this paper
• Stimuli‐Responsive Prodrug Chemistries for Drug Delivery

  2018cited by this paper
• Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.

  2018cited by this paper
• A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer

  2018cited by this paper
• Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial

  2018cited by this paper
• Hyaluronic Acid Surface Modified Liposomes Prepared via Orthogonal Aminoxy Coupling: Synthesis of Nontoxic Aminoxylipids Based on Symmetrically α-Branched Fatty Acids, Preparation of Liposomes by Microfluidic Mixing, and Targeting to Cancer Cells Expressing CD44.

  2018cited by this paper
• Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.

  2018cited by this paper
• Design and Development of Polysaccharide-Doxorubicin-Peptide Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-Penetrating Peptides for Cancer Chemotherapy.

  2018cited by this paper
• Rational Design of Cancer-Targeted Selenadiazole Derivative as Efficient Radiosensitizer for Precise Cancer Therapy.

  2018cited by this paper
• Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics

  2017cited by this paper
• Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.

  2017cited by this paper
• Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

  2017cited by this paper
• Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures

  2017cited by this paper
• Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs

  2017cited by this paper
• Antibody-targeted nanoparticles for cancer treatment.

  2016cited by this paper
• Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

  2016cited by this paper
• HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

  2016cited by this paper
• The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction.

  2016cited by this paper
• Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.

  2016cited by this paper
• Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

  2016cited by this paper
• Analysis of nanoparticle delivery to tumours

  2016cited by this paper
• To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

  2016cited by this paper
• Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.

  2016cited by this paper
• Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.

  2016cited by this paper
• Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles.

  2016cited by this paper
• Cancer Nanomedicine: From Targeted Delivery to Combination Therapy

  2015cited by this paper
• Liposomes as nanomedical devices

  2015cited by this paper
• Blended Nanoparticle System Based on Miscible Structurally Similar Polymers: A Safe, Simple, Targeted, and Surprisingly High Efficiency Vehicle for Cancer Therapy

  2015cited by this paper
• Design considerations for nanotherapeutics in oncology.

  2015cited by this paper
• Principles of nanoparticle design for overcoming biological barriers to drug delivery

  2015cited by this paper
• Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

  2015cited by this paper
• Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles.

  2015cited by this paper
• Targeted therapy using nanotechnology: focus on cancer

  2014cited by this paper
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

  2014cited by this paper
• Cancer-specific gene silencing through therapeutic siRNA delivery with B vitamin-based nanoassembled low-molecular-weight hydrogelators.

  2014cited by this paper
• Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

  2014cited by this paper
• Harnessing RNAi nanomedicine for precision therapy

  2014cited by this paper
• Hyaluronic Acid Conjugates as Vectors for the Active Targeting of Drugs, Genes and Nanocomposites in Cancer Treatment

  2014cited by this paper
• Polymer therapeutics: Top 10 selling pharmaceuticals - what next?

  2014cited by this paper
• The efficacy and safety of paclitaxel injection concentrate for nano-dispersion (PICN) at two different doses versus paclitaxel albumin-stabilized nanoparticle formulation in subjects with metastatic breast cancer (MBC).

  2014cited by this paper
• Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics.

  2014cited by this paper
• Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy

  2013cited by this paper
• Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

  2013cited by this paper
• Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.

  2013cited by this paper
• Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.

  2013cited by this paper
• Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

  2012cited by this paper
• The journey of a drug-carrier in the body: an anatomo-physiological perspective.

  2012cited by this paper
• Human tumor xenografts: the good, the bad, and the ugly.

  2012cited by this paper
• Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.

  2012cited by this paper
• The effect of nanoparticle size, shape, and surface chemistry on biological systems.

  2012cited by this paper
• The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

  2012cited by this paper
• Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles

  2012cited by this paper
• Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size.

  2011cited by this paper
• The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

  2011cited by this paper
• The role of nanomaterials in translational medicine.

  2011cited by this paper
• Criteria impacting the cellular uptake of nanoparticles: a study emphasizing polymer type and surfactant effects.

  2011cited by this paper
• Strategies in the design of nanoparticles for therapeutic applications

  2010cited by this paper
• Rexin-G, a targeted genetic medicine for cancer

  2010cited by this paper
• Delivering nanomedicine to solid tumors

  2010cited by this paper
• Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

  2010cited by this paper
• Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

  2010cited by this paper
• Targeting of albumin-embedded paclitaxel nanoparticles to tumors.

  2009cited by this paper
• The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

  2009cited by this paper
• Targeted therapies for prostate cancer against the prostate specific membrane antigen.

  2009cited by this paper
• Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer

  2009cited by this paper
• Tissue-penetrating delivery of compounds and nanoparticles into tumors.

  2009cited by this paper
• Understanding biophysicochemical interactions at the nano-bio interface.

  2009cited by this paper
• Impact of nanotechnology on drug delivery.

  2009cited by this paper
• Paul Ehrlich's magic bullet concept: 100 years of progress

  2008cited by this paper
• Active targeting schemes for nanoparticle systems in cancer therapeutics.

  2008cited by this paper
• Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.

  2008cited by this paper
• Renal clearance of quantum dots

  2007cited by this paper
• Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells.

  2007cited by this paper
• Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery

  2007cited by this paper
• Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

  2007cited by this paper
• In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.

  2006cited by this paper
• Complement Activation by Core–Shell Poly(isobutylcyanoacrylate)–Polysaccharide Nanoparticles: Influences of Surface Morphology, Length, and Type of Polysaccharide

  2006cited by this paper
• Clinical experience with denileukin diftitox (ONTAK).

  2006cited by this paper
• An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution.

  2005cited by this paper
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

  2004cited by this paper
• Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.

  2004cited by this paper
• Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts

  2004cited by this paper
• Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis.

  2004cited by this paper
• Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.

  2004cited by this paper
• Pathology: Cancer cells compress intratumour vessels

  2004cited by this paper
• Ligand-targeted therapeutics in anticancer therapy

  2002cited by this paper
• Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge.

  2001cited by this paper

• Targeted Nanodelivery of WGX50 and Curcumin via Gold Nanoparticles for Alzheimer's Therapy

  2026influential citation
• Emerging smart nanocarrier based drug delivery systems for cancer therapeutics

  2026cites this paper
• Targeted delivery of curcumin based on nanocarriers: potential therapeutic strategies for noninfectious arthritis.

  2026cites this paper
• In Vitro Assessment of a Paclitaxel-Poly(Caprolactone) Drug Delivery System in Endometrial Cancer.

  2025cites this paper
• Nano-immunotherapy: Merging immunotherapy precision with nanomaterial delivery

  2025cites this paper
• Folic acid-anchored liposomes in cancer therapy: a next-generation nanoplatform for precision drug delivery and tumor targeting.

  2025cites this paper
• Emerging Trends in the Application of Nanosuspension-Based Biomaterials for Anticancer Drug Delivery

  2025cites this paper
• A narrative review on the use of Green synthesized metallic nanoparticles for targeted cancer therapy.

  2025cites this paper
• Hybrid amorphous titanium dioxide/amphiphilic graft copolymer nano-sonosensitizers

  2025cites this paper
• Roadmap to Nanomedical Applications: Nanotoxicology and In Vitro Guidelines for Lanthanide‐Doped Luminescence Nanothermometers

  2025cites this paper
• Nanomedicine Targeting the Warburg Effect: Advanced Strategies for Cancer Therapy.

  2025cites this paper
• Nano-Sized Liposomes for Click-Chemistry-Based Selective Guiding of Immune Cells to Neuroblastoma

  2025cites this paper
• Site-Specific Transformable Nanostructures for Cancer Therapy and Diagnosis.

  2025cites this paper
• Interrogation of the Tumor Microenvironment by Nanoparticles.

  2025cites this paper
• Targeting lung cancer utilizing smart nanoparticles: Nanomedicine meets tumor stroma.

  2025cites this paper
• Revolutionizing cancer treatment: Nanotherapeutics targeting the tumor micro-environment.

  2025cites this paper
• Deciphering Evolution, Function, and Observation of Crystallization-Driven Self-Assembly

  2025cites this paper
• Targeting with toxins: an overview of venom peptides in drug delivery.

  2025cites this paper
• Poly(2-(diisopropylamino)ethyl methacrylate) as a pH-sensitive polymeric system for Colon cancer therapy

  2025cites this paper
• Phase-separating Pt(IV)-graft-glycopeptides sequentially sensing pH and redox for deep tumor penetration and targeting chemotherapy.

  2025cites this paper
• Mechanism of selenium-doped black phosphorus nanosheets wrapped with biomimetic tumor cell membrane for prostate cancer immunotherapy.

  2025cites this paper
• Docetaxel combined with silver nanoparticles for synergistic therapy of prostate cancer via effectively inhibiting cell proliferation and inducing apoptosis

  2025cites this paper
• Precision Nanomedicine: A Necessary Convergence of Nanodrug Development, Organotypic Models and Microphysiological Systems

  2025cites this paper
• Galloylated liposomes enable targeted drug delivery by overcoming protein corona shielding

  2025cites this paper
• Nanoparticles for chloroquine delivery: Enhancing its anticancer effect

  2025cites this paper
• Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology

  2025cites this paper
• Advanced Nanomaterials Functionalized with Metal Complexes for Cancer Therapy: From Drug Loading to Targeted Cellular Response

  2025cites this paper
• Potential of polysaccharides as active targeting agents for nanoparticles toward biological receptors: a review.

  2025cites this paper
• Nanoparticle-enhanced drug delivery systems: An up-to-date review

  2025cites this paper
• The Contribution of Nanomedicine in Ocular Oncology

  2025cites this paper
• Recent advances in the use of liquid crystalline nanoparticles for non-small cell lung cancer treatment

  2025cites this paper
• Advancing anticancer chelation therapy: Insights from enhancing cytotoxic potency, targeted cellular delivery, metal-based immunomodulation, and combinatorial strategies

  2025cites this paper
• Repurposing gemcitabine for glioblastoma treatment: the role of drug-conjugates and nanoparticles as drug delivery systems

  2024cites this paper
• Polymeric Nanoparticles for Drug Delivery

  2024cites this paper
• Non-vesicular nanocarriers for breast cancer management: current advances, challenges, and future perspective

  2024cites this paper
• Exploring contemporary breakthroughs in utilizing vesicular nanocarriers for breast cancer therapy.

  2024cites this paper
• Microfluidic-assisted formulation of cell membrane-camouflaged anisotropic nanostructures.

  2024cites this paper
• Nanoparticles Based on Polyferulic and Polygentisic Acids as New Carriers of Anticancer Drugs

  2024cites this paper
• Targeting the breast tumor microenvironment by plant-derived products and their nanoformulations

  2024cites this paper
• SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer

  2024cites this paper
• Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies

  2024cites this paper
• Targeted Delivery and Apoptosis Induction of CDK-4/6 inhibitor Loaded Folic Acid Decorated Lipid-Polymer Hybrid Nanoparticles in Breast Cancer cells.

  2024cites this paper
• Riboflavin-targeted polymers improve tolerance of paclitaxel while maintaining therapeutic efficacy.

  2024cites this paper
• Insights into Targeted and Stimulus‐Responsive Nanocarriers for Brain Cancer Treatment

  2024cites this paper
• Engendered nanoparticles for treatment of brain tumors

  2024cites this paper
• A review of design criteria for cancer-targeted, nanoparticle-based MRI contrast agents

  2024cites this paper
• Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.

  2024cites this paper
• Melanoma extracellular vesicles membrane coated nanoparticles as targeted delivery carriers for tumor and lungs

  2024cites this paper
• Peptide-nanoparticle conjugates as a theranostic platform

  2024cites this paper
• Nanotechnology in cancer therapeutics, diagnosis, and management

  2024cites this paper
• Novel paradigm of therapeutic intervention for skin cancer: challenges and opportunities

  2024cites this paper
• Realizing active targeting in cancer nanomedicine with ultrasmall nanoparticles

  2024cites this paper
• Design and translation of injectable biomaterials

  2024cites this paper
• Mechanism of RGD-conjugated nanodevice binding to its target protein integrin αVβ3 by atomistic molecular dynamics and machine learning.

  2024cites this paper
• Dual-pore protocells with multitasking capacities for simultaneous delivery of therapeutic enzymes and drugs in macrophage depletion therapy.

  2024cites this paper
• Recent composition and applications of liposomes in cancer therapy

  2024cites this paper
• Phase-separated cationic giant unilamellar vesicles as templates for the polymerization of tetraethyl orthosilicate (TEOS).

  2024cites this paper
• Scouting the efficacy of targeted gold nanoparticles in the landscape of cancer therapy

  2024cites this paper
• A critical review of various synthesis methods of nanoparticles and their applications in biomedical, regenerative medicine, food packaging, and environment

  2024cites this paper
• Polymeric Nanoparticles Containing Ruthenium Complexes for Biomedical Applications: A Mini-Review on Recent Developments

  2024cites this paper
• αvβ3 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment

  2024cites this paper
• Sequential Catalytic Nanomedicinal Utilization for Synergistic Drug Delivery Application in Cancer Nanotechnology

  2024cites this paper
• Strategies for the development of metalloimmunotherapies

  2024cites this paper
• Progress and Promise of Photoresponsive Nanocarriers for Precision Drug Delivery in Cancer

  2024cites this paper
• Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment

  2024cites this paper
• Introducing targeting units or pH-Releasable immunodrugs into Core-Clickable nanogels

  2024cites this paper
• To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges.

  2024cites this paper
• Designing Multivalent Copolymers for Selective Targeting of Multicomponent Surfaces

  2024cites this paper
• A functionalized cell membrane biomimetic nanoformulation based on layered double hydroxide for combined tumor chemotherapy and sonodynamic therapy.

  2024cites this paper
• Functional Noncentrosymmetric Nanoparticle-Nanofiber Hybrids via Selective Fragmentation.

  2024cites this paper
• Nano-based drug delivery systems in hepatocellular carcinoma

  2024cites this paper
• Hyaluronic acid-functionalized graphene-based nanohybrids for targeted breast cancer chemo-photothermal therapy.

  2024cites this paper
• Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges

  2024cites this paper
• Recent Advances in Nano-Based Drug Delivery Systems for Treatment of Liver Cancer.

  2024cites this paper
• Nanoparticles based on polyferylic and polygentisic acids as new carriers of anticancer drugs

  2024cites this paper
• AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy

  2024cites this paper
• Advancements in nanotechnology-driven photodynamic and photothermal therapies: mechanistic insights and synergistic approaches for cancer treatment

  2024cites this paper
• Bioorthogonal Drug Release from Nanometric Micelles in Living Cells.

  2023cites this paper
• GLUT1 transporter-facilitated solid lipid nanoparticles loaded with anti-cancer therapeutics for ovarian cancer targeting.

  2023cites this paper
• Recent Developments in Nanoparticle‐Based Photo‐Immunotherapy for Cancer Treatment

  2023cites this paper
• The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers

  2023cites this paper
• Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems.

  2023cites this paper
• Recent progress in nanotechnology-based drug carriers for resveratrol delivery

  2023cites this paper
• Nano‐biotechnology in tumour and cancerous disease: A perspective review

  2023cites this paper
• Super-resolution imaging of antibody-conjugated biodegradable periodic mesoporous organosilica nanoparticles for targeted chemotherapy of prostate cancer.

  2023cites this paper
• Nanovaccine Based on a Biepitope Antigen to Potentiate the Immunogenicity of a Neoantigen.

  2023cites this paper
• Development of Thiol-Maleimide hydrogels incorporating graphene-based nanomaterials for cancer chemo-photothermal therapy.

  2023cites this paper
• Lentinan: An unexplored novel biomaterial in drug and gene delivery applications.

  2023cites this paper
• Virus-like nanoparticles as enzyme carriers for Enzyme Replacement Therapy (ERT).

  2023cites this paper
• ROS-mediated anticancer effects of EGFR-targeted nanoceria.

  2023cites this paper
• Recent advances in nano/micro systems for improved circulation stability, enhanced tumor targeting, penetration, and intracellular drug delivery: a review

  2023cites this paper
• Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer.

  2023cites this paper
• Artificial Intelligence Aids in Development of Nanomedicines for Cancer Management.

  2023cites this paper
• Multifunctional mesoporous silica nanoparticles for biomedical applications

  2023cites this paper
• Selecting Counterions to Improve Ionized Hydrophilic Drug Encapsulation in Polymeric Nanoparticles.

  2023cites this paper
• Optimized DOX Drug Deliveries via Chitosan-Mediated Nanoparticles and Stimuli Responses in Cancer Chemotherapy: A Review

  2023influential citation
• Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights.

  2023cites this paper
• Trends in smart drug delivery systems for targeting cancer cells

  2023cites this paper
• Designed fabrication of active tumor targeting covalent organic framework nanotherapeutics via a simple post-synthetic strategy

  2023cites this paper
• Predicting efficacy of drug-carrier nanoparticle designs for cancer treatment: a machine learning-based solution

  2023cites this paper